Hugel Builds Direct US Sales Force for Letybo, Launches K-TOX Push
Hugel Aesthetics is deploying a direct US sales force for Letybo and a new K-TOX campaign, moving its botulinum toxin business to in-house commercial operations.
Topic
Botulinum Toxin
Topic
Botulinum Toxin
Chatelaine Maps the Wild, Semi-Regulated World of Botox Parties
Chatelaine published 'Inside The Wild, Semi-Regulated World Of Botox Parties,' a feature on injection services outside licensed c…
Health Canada Clears Allergan's Boey for Glabellar Lines
Health Canada has approved Boey, Allergan Aesthetics' rapid-onset, short-duration neuromodulator for glabellar lines — a new temp…
Ontario nursing regulator moves to ban med-spa Botox, fillers
Ontario's nursing regulator is moving to ban unsupervised Botox and dermal-filler injections at medical spas, the Toronto Star re…
TrenibotulinumtoxinE: A New Toxin Name Dermatologists Should Know
TrenibotulinumtoxinE is an early-stage type E botulinum toxin candidate, distinct from all approved type A products. Its reported…
FDA Issues Complete Response Letter for Galderma's RelabotulinumtoxinA
The US FDA has issued a Complete Response Letter to Galderma for relabotulinumtoxinA, halting the next-generation botulinum toxin…
FDA Requests More Manufacturing Data on Fast-Onset Toxin TrenibotE
The FDA has requested additional manufacturing information on TrenibotE, the quick-acting botulinum toxin candidate, according to…
FDA Accepts Galderma's BLA Resubmission for Its Liquid Toxin
The FDA has accepted Galderma's resubmitted BLA for its ready-to-use liquid botulinum toxin, restarting a review the agency previ…
Hugel Backs Physician-Led Research to Raise K-Aesthetics Profile
Hugel is funding physician-led research to build the clinical evidence base behind Korean aesthetic medicine as it competes globa…
Hugel Sets 1 Trillion Won Sales Target Within Three Years
Hugel targets 1 trillion won in sales within three years, staking its growth plan on the Korean aesthetics maker's injectable por…